HWM
EWTX icon

HighMark Wealth Management’s Edgewise Therapeutics EWTX Stock Holding History

HighMark Wealth Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.16M Hold
53,179
– – 0.72% 24
2026
Q1 		$1.68M Hold
53,179
– – 0.68% 21
2025
Q4 		$1.32M Hold
53,179
– – 0.54% 25
2025
Q3 		$863K Buy
53,179
+1,114
+2% +$15.8K 0.38% 35
2025
Q2 		$683K Buy
52,065
+51,900
+31,455% +$748K 0.33% 41
2025
Q1 		$3.63K Hold
165
– – ﹤0.01% 402
2024
Q4 		$4.41K Buy
+165
New +$5.25K ﹤0.01% 392

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HighMark Wealth Management's EWTX Position: Q2 2026 in Review

HighMark Wealth Management held its Edgewise Therapeutics (EWTX) position steady in Q2 2026 at 53,179 shares worth $2.16M. The position accounts for 0.72% of the portfolio, ranked #24.

HighMark Wealth Management first reported a position in EWTX in Q4 2024 and has held it in 7 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • HighMark Wealth Management held 53,179 shares of Edgewise Therapeutics worth $2.16M as of Q2 2026.
  • HighMark Wealth Management left its Edgewise Therapeutics share count unchanged in Q2 2026.
  • Edgewise Therapeutics made up 0.72% of HighMark Wealth Management's portfolio in Q2 2026, its #24 holding.
  • HighMark Wealth Management first reported a position in Edgewise Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.